Advanced Filters
noise

Glebe, Australia Clinical Trials

A listing of Glebe, Australia clinical trials actively recruiting patients volunteers.

Found 368 clinical trials
U Umesh Tulachan

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: What medical problems do participants have when taking GT-02287? How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)? Are there …

30 - 85 years of age All Phase 1
E Elisa Cornish

Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.

18 - 85 years of age All Phase 2
V Varlli Scott

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.

18 - 65 years of age All Phase 1/2
E Erin Cassidy

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1). The main questions it aims to answer are: How well participants are able tolerate different doses of PAS-004, and What side effects PAS-004 might …

18 years of age All Phase 1
A Alexander Guminski

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

11 - 50 years of age All Phase 3
M Mayra Ouriques

Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression

The goal of this study is to compare the effectiveness of two formulations of ketamine - Spravato® and racemic ketamine - in people with treatment-resistant depression (TRD). The main questions it aims to answer are: How the two formulations compare in terms of their effectiveness in treating TRD. How the …

18 years of age All Phase 4
H Hanlon Sia, MBBS(Adelaide), FRACP, FRCPA

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).

18 years of age All Phase 1
M Michael Solomon, DMed

PRIORITY-CONNECT 2 Pilot Trial

The provision of preoperative interventions (prehabilitation: including exercise, nutrition, and psychological treatment) have been reported to reduce postoperative complications by as much as 50% and reduce hospital stay by up to 4 days compared to standard of care. Postoperative multimodal interventions are likely to further benefit patients facing new challenges …

18 years of age All Phase N/A

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for …

18 years of age All Phase 1/2

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.

18 years of age All Phase 1

Simplify language using AI